Medical information notice: This article is for informational reference only. It does not constitute diagnosis, treatment, medication, or advice on seeking medical care in Japan, and it cannot replace in-person consultation with a physician. For matters involving medicines, examinations, clinical trials, or regenerative-medicine indications, please rely on the latest public information from medical institutions and competent authorities, and seek assessment by a qualified physician.
Information status: July 7, 2026. This article is organized from public information from the Southern Tohoku Proton Therapy Center, Jiahui Health, and others, and is supplemented and rewritten with reference to the original WeChat article.
In April 2026, a team from the Southern Tohoku General Hospital visited Shanghai, participated in an international medical expo, held special lectures, and signed a memorandum of understanding (MOU) with Shanghai Jiahui International Hospital and Japan’s Emergency Assistance Japan. The significance of this lies not in creating a “sole referral channel,” but in the fact that information exchange on advanced cancer treatment between China and Japan is moving from individual consultations toward more institutionalized collaboration.
1. Southern Tohoku Hospital’s core resources: BNCT and proton therapy
The Southern Tohoku Hospital system is located in Koriyama City, Fukushima Prefecture. Its Southern Tohoku BNCT Research Center and Southern Tohoku Proton Therapy Center are its two most internationally noticed cancer-treatment platforms.
BNCT, or boron neutron capture therapy, is a radiation-therapy method that combines a boron-containing drug with neutron irradiation. According to the Southern Tohoku BNCT Research Center website, in Japan it has been used, within insurance coverage, for the treatment of unresectable locally advanced or recurrent head and neck cancer. Proton therapy belongs to particle-beam therapy, and through the advantage of dose distribution it reduces irradiation of some normal tissue.
Neither of these two technologies is an “all-purpose anti-cancer solution.” Whether they are suitable depends on the cancer type, location, prior treatment, extent of the tumor, overall physical condition, and imaging and pathology data.
2. What this Shanghai event involved
According to official news from the Southern Tohoku Proton Therapy Center, the hospital went to Shanghai from April 22 to 26, 2026, participated in the Shanghai International Medical Expo, held lectures on BNCT and proton therapy at United Family Hospital, and signed the MOU with Shanghai Jiahui International Hospital. Jiahui also released news related to a global BNCT treatment network.
For patients, the value of the expo and lectures is mainly to make information more transparent: which cancer types might be suitable for consulting about BNCT? Which situations are more suitable for proton therapy? After recurrence following prior radiotherapy, is there still room for local treatment? In the past, such questions were often spread in a fragmented way; now there is an opportunity to form more standardized communication between hospitals and professional teams.
3. What role Shanghai Jiahui International Hospital plays in this
Shanghai Jiahui International Hospital is a general hospital oriented toward internationalized medical services, with long-standing experience cooperating with overseas medical institutions. Its cooperation with the Southern Tohoku team does not mean that all patients must travel to Japan through a single path; rather, it provides a bridge that makes it easier to organize records, evaluate imaging, communicate remotely, and coordinate referrals.
4. The practical significance of the MOU for Chinese patients
- Clearer information: patients can learn earlier whether they fall within the scope that can be consulted, reducing blind travel.
- More standardized records: imaging, pathology, and treatment history can be organized according to the Japanese hospital’s needs, improving the efficiency of initial assessment.
- More transparent communication: the purpose, limits, waiting time, cost, and risks of treatment can be confirmed before travel.
- More continuous collaboration: domestic hospitals, support organizations, and the Japanese hospital can form a closed loop before, during, and after consultation.
5. Which patients are suitable for further consultation
Those who may consider consultation are generally patients who have completed a clear pathological diagnosis, have local recurrence or a need for local control, have limited standard-treatment options, and wish to evaluate the feasibility of BNCT or particle-beam therapy. In particular, patients with recurrent head and neck cancer, some cases that have previously received radiotherapy, or those who wish to understand local-treatment alternatives are more suited to first undergo a records assessment.
It is not advisable to understand BNCT or proton therapy as a “last resort.” The earlier a multidisciplinary assessment is carried out, the easier it is to determine a reasonable order among local treatment, systemic treatment, surgery, and clinical trials.
6. Points that require caution
In Japan, BNCT has already entered insured treatment for specific indications, but other cancer types may still be at the clinical-research or case-by-case evaluation stage. Proton therapy likewise requires strict indication judgment. Cross-border medical information often features “miracle cure” narratives; patients should give priority to trusting hospital official websites, clinical-trial registries, official news, and the opinion of the attending physician.
Conclusion
The cooperation between Southern Tohoku Hospital and Shanghai Jiahui International Hospital is a visible node in China-Japan collaboration on advanced cancer treatment. Its real value is not in creating a single entry point for patients, but in making complex technologies such as BNCT and proton therapy more standardized at the levels of consultation, assessment, and referral.